Short answer
Sanara MedTech Inc. (SMTI) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces Sanara MedTech’s financial results for the quarter ended September 30, 2026.
Sanara MedTech Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces Sanara MedTech’s financial results for the quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed quarterly results and management commentary for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $28.4M, up 8%, led by soft tissue repair sales up 10% to $25.7M
- Gross margin held at 93%, while operating income fell to $0.7M from $2.9M amid $3.0M merger-related costs
- Adjusted EBITDA increased to $5.6M from $4.9M, indicating underlying earnings growth despite elevated transaction spending
- Cash $16.8M versus $46.7M long-term debt, with CRG interest timing favorably boosting quarter-end cash by approximately $1.6M
- Full-year revenue guidance cut to $110M-$115M from $116M-$121M, signaling slower expected growth despite merger progress with MIMEDX
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Sanara MedTech Inc. 8-K filings
Get the next SMTI 8-K as it lands
Follow SMTI for push alerts, or ask the research agent what this filing means.